Head-to-head · Cost-Efficiency Index
Woodwork vs MDLive
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Woodwork
Cost-first shoppers who want grindr users or men already comfortable with the brand who want ED, GLP-1, and peptide/supplement care bundled under one telehealth account.
Visit WoodworkMDLive
Cost-first shoppers who want not a fit for GLP-1 price shopping -- best suited to patients who already have MDLIVE access for general primary care.
Visit MDLiveThe verdict
Woodwork takes it, leading the Cost-Efficiency Index 51 to 50. Woodwork is a Grindr-operated telehealth platform primarily known for ED medications that also offers a dedicated GLP-1 line (compounded semaglutide from $127/mo, tirzepatide from $199/mo), plus muscle-growth peptides and supplements. MDLive still earns a C — Cost-first shoppers who want not a fit for GLP-1 price shopping -- best suited to patients who already have MDLIVE access for general primary care.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Woodwork.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Woodwork | MDLive |
|---|---|---|
| Cost-Efficiency Index | 51/100 | 50/100 |
| Semaglutide / mo | $127/mo (starting dose, compounded oral) | Not disclosed |
| Tirzepatide / mo | $199/mo (starting dose, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $1,524 | — |
| Tirzepatide / yr (modeled) | $2,388 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | Yes | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #405 | #410 |
Woodwork
51/100Where the value is
- Backed by an established consumer brand (Grindr LLC) with real infrastructure
- Competitive 'from' pricing on both semaglutide ($127/mo) and tirzepatide ($199/mo)
- Oral tablet option available for semaglutide in addition to injections
The tradeoffs
- GLP-1 is a secondary offering -- the platform's primary identity and marketing focus is ED medication, not weight loss
- No named medical director or clinical leadership found on any accessible page
MDLive
50/100Where the value is
- Backed by a major, established telehealth/insurance parent (Evernorth/Cigna)
- Access to FDA-approved branded anti-obesity medications, not unregulated compounds
- Broad general primary-care telehealth infrastructure
The tradeoffs
- No dedicated GLP-1 or weight-loss program -- medications are folded into general primary care visits only
- No medication-specific pricing published anywhere
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.